A new molecule discovered by Swiss scientists, ADX71743, could prove to be a breakthrough in the treatment of anxiety disorders and post-traumatic stress disorder (PTSD). Scientists at the University of Lausanne and the Lausanne University Hospital set out to study the process of how our brain stores and updates traumatic memories.
Current medications, such as benzodiazepines, often provide only temporary relief and carry risks such as tolerance, dependency, and the recurrence of fear after treatment is discontinued. The Swiss researchers’ study, however, offers a completely different approach.
Key Research Findings
Central to the research is a process called reconsolidation. Every time a person recalls a traumatic memory, that memory becomes temporarily unstable in the brain before being returned to memory storage. It is during this short window that it is possible to influence the memory.
The molecule ADX71743 specifically targets mGlu5 receptors, which play a crucial role in memory formation. Preclinical experiments on rats showed that the use of this molecule during the memory recall process significantly reduced fear responses in the days that followed.
The primary advantage of the ADX71743 molecule is that it does not erase memories, but rather weakens the fear associated with them. This means that while a person retains the information about what happened, the traumatic experience becomes emotionally less painful. Scientists suggest that the medication would be most effective when combined with psychotherapy.
Perspectives
Although the research is still in the preclinical stage, the effect has already been confirmed in both animals and human brain tissue samples. This approach fundamentally changes existing methods of treating anxiety; instead of merely suppressing symptoms, science is now attempting to alter the brain’s mechanism for processing fear. This raises hopes that, in the future, the treatment of trauma-related disorders will be much more effective and resilient against relapse.
